Viatris
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.www.viatris.com
28
MENTIONS
14
EPISODES
11
PODCASTS
Search complete. 28 mentions across 14 episodes found for "Viatris".
Oct 19, 2026
Maya PatelHOST
The second approval is a new use for an existing product.
Maya PatelHOST
Viatris' Rhizome V, Phentolamine eye drops at 0.75%, was already used to reverse drug-induced pupil dilation.
Maya PatelHOST
FDA has now added presbyopia in adults, the age-related loss of near focus.
Alex MercerHOST
The Vega 3 trial randomized 569 adults aged 45 to 64 and compared the drops with vehicle drops.
Alex MercerHOST
The new indication is presbyopia in adults, the age-related loss of near-focusing.
Alex MercerHOST
Opus Genetics licensed the drops to Viatris, which holds exclusive US commercialization rights.
Alex MercerHOST
Viatris says it's exploring a US partner to commercialize them for presbyopia.
Maya PatelHOST
In the Vega three trial, the drops were compared with inactive vehicle drops in adults aged forty-five to sixty-four.
Maya PatelHOST
The main measurement looked for a symptomatic improvement in near vision on day eight, twelve hours after dosing.
Asif SuriaHOST
Please also take a moment to like and subscribe to this podcast on whatever platform you may be listening on.
Tamanna SuriaHOST
Today, we wanted to focus on three key stories, including the potential acquisition of the toy company Mattel by two potential bidders, an unusual combination of Chipotle and Starbucks, and the generic drugs company Viatris buying the pain medications-focused company Pacira Biosciences.
Tamanna SuriaHOST
Before we begin, we want to state that nothing on this podcast is meant as investment advice.
Tamanna SuriaHOST
We or our clients may have a position in any of the stocks discussed.
16 MINS LATER
Asif SuriaHOST
The company has a couple of FDA-approved drugs and has the same drugs in Phase 3 trials for different indications.
Asif SuriaHOST
It also has several additional drugs to treat other conditions, including dry eye disease, in various stages ranging from preclinical to Phase 2.
Asif SuriaHOST
Getting back to the announced deal, not only was Pesaira a familiar name for us, Viatris was also a familiar name.
Asif SuriaHOST
And we mentioned it a few times on this podcast when discussing reverse modest trust transactions.
Alex MercerHOST
The Daily Roundup starts in pain.
Alex MercerHOST
Viatris has agreed to acquire Pacira Biosciences for thirty-six dollars and fifty cents a share in cash, about one point six five billion dollars in equity value.
Alex MercerHOST
Pacira markets two non-opioid pain injections, Exparel for use after surgery and Zilretta for knee osteoarthritis.
Alex MercerHOST
Pacira’s total revenue was about seven hundred forty-six million dollars over the twelve months through June.
Alex MercerHOST
Viatris ties the deal to its non-opioid pain strategy.
Alex MercerHOST
Closing is expected by year-end, subject to conditions.
Maya PatelHOST
In Medicare policy, the drug industry’s trade group, PhRMA, filed a complaint Wednesday asking a federal court to declare CMS’ Globe model unlawful and vacate it.
DashaNARRATOR
The company's shares rose three point seven percent.
DashaNARRATOR
Pacira Biosciences have had shares surge forty-four percent after Viatris agreed to acquire the company for one point six five billion dollars.
DashaNARRATOR
Home buyers are ha-- Home builders are having a tough month.
DashaNARRATOR
Mortgage rates just hit a three-week high, putting more of the pressure on shares of home builders already in the doldrums.
DashaNARRATOR
The company's shares rose three point seven percent.
DashaNARRATOR
Pacira Biosciences have had shares surge forty-four percent after Viatris agreed to acquire the company for one point six five billion dollars.
DashaNARRATOR
Home buyers are ha-- Home builders are having a tough month.
DashaNARRATOR
Mortgage rates just hit a three-week high, putting more of the pressure on shares of home builders already in the doldrums.
Pierre BienaiméHOST
Shares rose three point seven percent.
Pierre BienaiméHOST
And shares in the pain drug maker Pacira Biosciences surged more than forty percent after Viatris agreed to buy it for one point six five billion dollars.
Pierre BienaiméHOST
Viatris ended the day down point three percent.
Pierre BienaiméHOST
Heads up, an artificial intelligence tool helped us make this episode by creating summaries that were based on WSJ reporting and then reviewed and adapted by an editor.
Pierre BienaiméHOST
We'll have more coverage of the day's news on the WSJ's What's News? podcast.
Romaine BostickHOST
Uh, I'm gonna go over to something a little bit different.
Romaine BostickHOST
Ticker is PCRX, uh, Pacira Bio- Biosciences, I'm hopefully saying it correctly, uh, surging the most intraday on record, up 44% here at the close after Viatris agreed to buy the firm for 36.50 a share, representing equity value of about 1.65 billion, 45% premium to the Wednesday close.
Romaine BostickHOST
Deal expected to close at the end of the year.
Romaine BostickHOST
Why is this happening? Uh, this is about expanding into the non-opioid, opioid pain market.
4 more episodes mention Viatris.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.